New therapeutic approaches in asthma.
Reed
C E
CE
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000336:Aerosols; D000402:Airway Obstruction / Q000503:physiopathology; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D001249:Asthma / Q000139:chemically induced / Q000188:drug therapy*; D001980:Bronchi; D001993:Bronchodilator Agents / Q000627:therapeutic use; D019819:Budesonide; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004837:Epinephrine / Q000627:therapeutic use; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006046:Gold / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D009092:Mucous Membrane / Q000473:pathology; D010024:Osteoporosis / Q000139:chemically induced; D010276:Parasympatholytics / Q000627:therapeutic use; D010353:Patient Education as Topic; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D011282:Pregnenediones / Q000627:therapeutic use; D013806:Theophylline / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D000336:Aerosols; D001993:Bronchodilator Agents; D002121:Calcium Channel Blockers; D005938:Glucocorticoids; D010276:Parasympatholytics; D011282:Pregnenediones; D019819:Budesonide; D006046:Gold; D013806:Theophylline; D004205:Cromolyn Sodium; D001241:Aspirin; D011241:Prednisone; D004837:Epinephrine